3 Rinne UK. Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand Suppl, 1983,95:19-26.
4 Mourakian MM, Chase TN. Levodopa response fluctuation in Parkinson's disease. Clin Neuropharmacol, 1988,11:378-385.
5 Fabbrini G, Moruadian MM, Juncoo JL, et al. Motor fluctuations in Parkinson's disease. central pathophysiological mechanism. Part I. Ann Neurol, 1988,24:366-371.
6 Jorga KM, Dingemanse J, Fotteler B, et al. Effect of a novel COMT-inhibitor on L-Dopa pharmacokinetic when combined with different Madopar formulations. New Tr Clin Neuropharmacol, 1994,8:274.
7 Rayput AH, Martin W, Saint-Hilaire MH. Tolcapone improves motor function in parkinsonian patients with the “wearing off” phenomenon: a double-blind, placebocontrol, multicenter trial. Neurology, 1997,49:1066-1071.
8 Myllyla VV, Jackson M, Larsen JP, et al. Efficacy and safety of tolcapone in Levodopa-treated Parkinson's disease patients with “wearing off” phenomenon: a multicentre, double blind, randomized, placebo-controlled trial. Europ J Neurol, 1997,4：333-341.
9 Kurth MC, Adlcr CH, Hilaire ST, et al. Tolcapone improve motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuation: a multitcenter, double-blind, randomized, placebo-controlled trial. Neurology, 1997，48：81-87.
